C4 Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- C4 Therapeutics's estimated annual revenue is currently $34M per year.
- C4 Therapeutics's estimated revenue per employee is $219,161
- C4 Therapeutics's total funding is $273.8M.
- C4 Therapeutics's current valuation is $1.3B. (January 2022)
Employee Data
- C4 Therapeutics has 155 Employees.
- C4 Therapeutics grew their employee count by 29% last year.
C4 Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Staff to CEO | Reveal Email/Phone |
2 | SVP, Regulatory | Reveal Email/Phone |
3 | SVP, Technical Operations, Quality and Facilities | Reveal Email/Phone |
4 | VP, Head Clinical Pharmacology | Reveal Email/Phone |
5 | SVP, Biological Sciences | Reveal Email/Phone |
6 | SVP, Chemistry | Reveal Email/Phone |
7 | Head Facilities | Reveal Email/Phone |
8 | VP, Quality | Reveal Email/Phone |
9 | VP, Lead Discovery | Reveal Email/Phone |
10 | VP, Clinical Development | Reveal Email/Phone |
C4 Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is C4 Therapeutics?
C4 Therapeutics is pioneering a new class of drugs. C4's technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$273.8M
Total Funding
155
Number of Employees
$34M
Revenue (est)
29%
Employee Growth %
$1.3B
Valuation
N/A
Accelerator
C4 Therapeutics News
C4 Therapeutics (CCCC) Research Analysts' Weekly Ratings Changes · 4/18/2022 C4 Therapeutics had its price target lowered by analysts at UBS...
Get C4 Therapeutics alerts: 70.1% of C4 Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PharmaCyte Biotech...
C4 is a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of...
C4 Therapeutics, Inc., a Watertown, Mass.-based biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, closed a $170m financing. This included $150m in Series B equity co-led by existing investor Cobro Ventures and ...
C4 Therapeutics, a Cambridge, MA-based developer of novel treatments in the field of targeted protein degradation, closed a $73m Series A round of financing. The round was led by Cobro Ventures with participation from Cormorant Asset Management, The Kraft Group, EG Capital Group, Roche, Novarti ...
Other Companies in Watertown
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $24.8M | 160 | 7% | N/A |
#2 | $24.8M | 160 | 7% | N/A |
#3 | $17.9M | 163 | 5% | N/A |
#4 | $33.3M | 168 | 7% | N/A |
#5 | $18.9M | 172 | 15% | N/A |